



Editorial team

Editor-in-chief: Lanjing Zhang

Associate Editor: Shuhan

Wang

Assistant Editor: He Wang

Section Editors

Research Highlights:

Zhenghe

John Wang

Announcements: Shuhang

Wang

Advertisements: Nancy Du

Web Publishing: Wenwei Hu

WeChat Liaison: Zhongyu Li

Inside this issue:

President's welcome message	1
Annual meeting seminar series	2
Members' research highlights	4
Stop the hate crimes and racisms	6
Funding alerts	7
About the president	8
Journal: Genes & Diseases	9
Job openings	10
How to become a member	12
Management team	13
Past president's remarks	13

Volume 2, Issue 7

June 2021

President's welcome message

Dear Colleagues and Friends,

I am extremely honored to receive the baton to lead the Association of Chinese American in Cancer Research (ACACR). Under the leadership of Dr. Shi-Yuan Cheng and Dr. Zhenkun Lou in the past 4 years, the ACACR has rapidly grown with now over 700 people in two WeChat groups, including over 500 US-based faculty members in many universities, cancer centers, and medical schools. It has truly become an organization that represents us and operates on our behaviors.

We have successfully established a variety of activities to serve our community. Despite the pandemic, we have maintained robust scientific communications by organizing the annual meeting in the format of virtual seminars. The seminar series in 2020 was highly successful and received many positive feedbacks. This year, we have secured 26 outstanding speakers from June 13th to September 3rd to cover key areas in cancer research. We have also planned panel discussion meetings on important topics such as career development, tenure/promotion, and grantsmanship. We have continued to work with fellow organizations to voice our opinions and concerns. ACACR is among 34 physician and scientist organizations that published the open letter "Stop hate crimes and racism" in May 28th issue of Science. We have continued our collaboration with AACR and nominated our members to serve in AACR subcom-

mittees and journal editorial boards. Our newsletters have been quite timely and informative. The ACACR-affiliated journal *Genes & Diseases* received its first impact factor of 4.8 in 2020 and is expected to do even better this year. The success of these activities has sparked enthusiasm among our members to serve by running for vacant leadership and committee positions in March.

In this challenging period time, it is never more important for us to unite and work together as a group to show our spirits, strength, endurance, collegiality, and all other positive sides, and to establish our image as a powerful and reliable force in winning the war against cancer. We need your help to participate in all of our activities, fulfil the duties of membership, and step up to serve in our community. I look forward to closely working with you in this and next years!

Lin Zhang, PhD

President

Association of Chinese Americans in Cancer Research (ACACR)

Professor

UMPC Hillman Cancer Center

Department of Pharmacology & Chemical Biology

University of Pittsburgh School of Medicine
Pittsburgh, PA 15213-1863

Phone: 412-623-1009; Fax: 412-623-7778

Email: zhanglx@upmc.edu

The ACACR annual meeting seminars

Dear members and friends,

Hope this email finds you in great summer spirit.

After a highly successful virtual annual meeting seminar series last year, ACACR is planning to have virtual annual meetings again this summer.

With the hard work of the planning committee, we have secured 26 outstanding speakers, such as Shi Yang, Junjie Chen, Xi He, Wei Gu, Yibin Kang, Jean Zhao, Duojia Pan, and Yung-Chi Cheng..... just to name a few here, to cover topics in almost all cancer research areas. The virtual meetings will be held via Zoom on Fridays from

3:00 pm to 4:30 pm EST, from June 11th to September 3rd, 2021. Two speakers will present in each session with 10 min Q & A after each talk.

In response to request of many young PIs, we will also have two Panel Discussion Meetings (1st one on 07/01) on Career Development/Promotion and Grantsmanship, with department chairs and highly successful senior PIs as panel members.

Please mark your calendar and stay tuned. We will follow up with details in early next week, which will also be posted in our WeChat group and ACACR web-

site, and also sent to most of you by email as well.

We thank all of the invited speakers for supporting the mission of ACACR. We invite all the members and friends in our community to participate this exciting event.

Best regards,

2021 ACACR Virtual Annual Meeting Committee

Gengseng Feng, PhD, Tong-Chuan He, MD, PhD, Lin Zhang, PhD, Shiyuan Cheng, PhD, Zhenkun Lou, PhD, Gloria Su, PhD, Yong Li, PhD, Erxi Wu, PhD

Agenda of the ACACR annual meeting seminars (also available online)

Zoom Link: <https://columbiacuimc.zoom.us/j/95801089979?pwd=NUJoWm42QnMIWGV3SUIFTC90SGNwZz09>

Meeting ID: 958 0108 9979; Passcode: 084720

Zoom Meeting Managers: Gloria Su, Yong Li, and Lin Zhang

Date	Time	Speaker	Title	Person in Charge
June 11	3:00-3:10pm EST	Lin Zhang, PhD/UPMC President, ACACR	Welcome and Introduction	Gensheng Feng
	3:10-3:40pm EST	Yang Shi, Oxford	Epigenetic mechanisms controlling tumor immunity and therapy	
	3:40-3:50pm EST	Q & A		
	3:50-4:20pm EST	Qi Cao, Northwestern	A novel PRC2-independent role for EZH2 in rRNA 2'-O methylation and IRES-dependent translation	
	4:20-4:30pm EST	Q & A		
June 18	3:00-3:30pm EST	Xiaolu Yang, PhD/UPENN	In search of the fundamental elements for oncogenic transformation	Zhenkun Lou
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Junjie Chen, MD Anderson	Targeting DNA damage pathways in cancer therapy	
	4:10-4:20pm EST	Q & A		
June 25	3:00-3:30pm EST	Yiping Han, Columbia	Fusobacterium nucleatum in colorectal cancer: a story of two kingdoms	Gloria Su
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Jun Wu, UTSW	Dynamic Pluripotent Stem Cell States and Their Applications	
	4:10-4:20pm EST	Q & A		

Date	Time	Speaker	Title	Person in Charge
July 1	4:00-5:30pm EST	Panel Members: Yibin Kang, Rong Li, Hua Lu, Dihua Yu	Panel Discussion: Career Development, Promotion, and Tenure	Gensheng Feng
July 2	3:00-3:30pm EST	Xi He, Harvard	Understanding Wnt Signaling in Vertebrate Development and disease pathogenesis	Shiyuan Cheng
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Yong Wan, Northwestern	Targeting posttranslational modifications in breast carcinogenesis and therapy	
	4:10-4:20pm EST	Q & A		
July 9	3:00-3:30pm EST	Qiufu Ma, DFCI		Erxi Wu
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Shiyuan Cheng, Northwestern		
	4:10-4:20pm EST	Q & A		
July 16	3:00-3:30pm EST	Qing Zhang, UTSW		Yong Li
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Lee Zou, MGH		
	4:10-4:20pm EST	Q & A		
July 23	3:00-3:30pm EST	Dong-Er Zhang, UCSD		Gensheng Feng
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Hua Yu, City of Hope		
	4:10-4:20pm EST	Q & A		
July 30	3:00-3:30pm EST	Wenshe Liu, TAMU		Shi-Yuan Cheng
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Qin Yan, Yale		
	4:10-4:20pm EST	Q & A		
August 6	3:00-3:30pm EST	Wei Gu, PhD, Columbia		Gloria Su
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Weiping Zou, Univ of Michigan		
	4:10-4:20pm EST	Q & A		
August 13	3:00-3:30pm EST	Yibin Kang, Princeton		Zhenkun Lou
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Haojie Huang, Mayo		
	4:10-4:20pm EST	Q & A		
August 20	3:00-3:30pm EST	Boyi Gan, MD Anderson		Yong Li
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Jean Zhao, DFCI		
	4:10-4:20pm EST	Q & A		
August 27	3:00-3:30pm EST	Duojia Pan, UTSW		Lin Zhang
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Xiang Zhang, BCM		
	4:10-4:20pm EST	Q & A		
September 3	3:00-3:30pm EST	Li Ma, MD Anderson		Erxi Wu
	3:30-3:40pm EST	Q & A		
	3:40-4:10pm EST	Yung-Chi Cheng, Yale		
	4:10-4:20pm EST	Q & A		

Members' Research Highlights

Dr. **Shi-Yuan Cheng** at Northwestern University discovered that the CK2 α -PRMT6-RCC1 signaling axis that regulates the mitotic process, which contributes to the tumorigenicity and therapy response of glioblastoma stem cells. <https://www.sciencedirect.com/science/article/pii/S1097276521000150?via%3Dihub>. Moreover, they also found that a circRNA-encoded an oncogenic E-cadherin variant which promotes GBM tumorigenicity through activation of EGFR-STAT3 signaling. <https://www.nature.com/articles/s41556-021-00639-4>

Dr. **Deliang Guo** at the Ohio State University discovered that glioblastomas upregulate diacylglycerol-acyltransferase I (DGAT1) to store excess FAs into triglycerides and lipid droplets, and targeting this process could be a promising therapeutic approach. <https://www.sciencedirect.com/science/article/pii/S155041312030303X>

Dr. **Yu-Ying He** at the University of Chicago discovered that the m⁶A mRNA demethylase FTO is degraded by selective autophagy, and dysregulation of this process plays a key role in promoting tumorigenesis caused by arsenic exposure. <https://www.nature.com/articles/s41467-021-22469-6>

Dr. **Jian Jian Li** at UC Davis reported that CD47-mediated anti-phagocytosis is concurrently upregulated with HER2 in radioresistant breast cancer (BC) cells and RT-treated mouse syngeneic BC. <https://www.nature.com/articles/s41467-020-18245-7>

Dr. **Yong Li** at Baylor College of Medicine discovered that the E3 ligase RNF138 catalyzes K63-linked nonproteolytic polyubiquitination of oncogenic MYD88 L265P mutant protein, but not the WT MYD88. This novel finding provides a therapeutic opportunity to target MYD88 L265P mutant protein for leukemia. <https://doi.org/10.1182/blood.2020004918>. In addition, the Li lab reported that ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation, implicating TRAF4 as a pivotal intermediate in the ATR-CHK1 axis. <https://doi.org/10.1186/s13045-020-00869-3>.

Dr. **Zhenkun Lou** at the Mayo Clinic had an extremely productive year despite the pandemic. His laboratory published nearly 30 papers. The high-impact ones are highlighted here.

- Proton irradiation induces severe DNA damages that require the HR pathway and ATM. <https://cancerres.aacrjournals.org/content/early/2021/02/12/0008-5472.CAN-20-2960.long>
 - SARS-CoV-2 protein nsp13 uses host deubiquitinase USPI3 to stabilize itself and inhibits the MAVS-TBK1 innate immunity pathway. <https://www.nature.com/articles/s41392-021-00509-3>
 - GTP/GDP exchange factors DOCK7 has a previously unidentified role in regulating DNA repair by promoting RPA loading on the chromatin through the Rac1/Cdc42-PAK1 pathway.
 - RNA sensor RIG-I interacts with DNA repair factor XRCC4 and has a novel function in regulating DNA repair as well as innate immunity. <https://www.nature.com/articles/s41467-021-22484-7>
 - The DNA primase PrimPol is upregulated by USP36 following the replication stress, and USP36 inhibition can be explored to sensitize tumors to chemotherapy. <https://academic.oup.com/nar/article/48/22/12711/6006199>
 - CtIP has an inhibitory mono-ubiquitination that needs to be removed by the deubiquitinase USP52 to promote HR. <https://www.nature.com/articles/s41467-020-19202-0>
 - Extracellular matrix stiffness regulates DNA repair capability and tumor sensitivity to radiation and chemotherapy through regulating the ubiquitin pathway. <https://advances.sciencemag.org/content/6/37/eabb2630>
 - The protease SPRTN repairs the DNA-protein crosslink and prevents premature aging. <https://www.sciencedirect.com/science/article/pii/S1097276520304299?via%3Dihub>
 - The Ser/Thr kinase STK38 has a new kinase-independent function in activating ATM by functioning as a reader of histone H4 ufmylation. <https://advances.sciencemag.org/content/6/23/eaax8214>
-

Members' Research Highlights (Cont'd)

- PD-L1 has a novel nuclear function in regulating genomic stability. <https://www.nature.com/articles/s41422-020-0315-8>

Dr. **Zhenghe John Wang** discovered that a combination of glutaminase inhibitor CB-839 and 5-FU inhibits PIK3CA mutant colorectal cancers and perform a phase I clinical trial of the drug combination in human patients showing promising results. <https://cancerres.aacrjournals.org/content/80/21/4815.long>

Dr. **Lizi Wu** at University of Florida showed an essential role of the CRTC-CREB activation in promoting the malignant phenotypes of LKB1-null lung cancer and proposes the CRTC-CREB interaction interface as a novel therapeutic target. <https://doi.org/10.7554/elife.66095>

Dr. **Jindan Yu** at Northwestern University discovered that polycomb group protein EZH2 methylates a non-histone substrate FOXA1, which turns out to a critical therapeutic target of EZH2 inhibitors. <https://advances.sciencemag.org/content/7/15/eabe2261>

Dr. **Lanjing Zhang** at Rutgers University also had a very high productive year on AI studies on cancer and COVID-19.

State- and mobility-heterogeneity in the associations of public health interventions and human mobility with the changes of COVID-19 epidemics in the European Union. <https://pubmed.ncbi.nlm.nih.gov/33312379/>

The high correlation between search terms related to COVID-19 and trends in COVID-19 daily incidence and deaths in the US. <https://pubmed.ncbi.nlm.nih.gov/32348380/>

Used a model based on Farr's law to predict the daily incidence of COVID-19 infections in China (<https://pubmed.ncbi.nlm.nih.gov/32355547/>)

Identified underlying causes of death in the US with mortality trends in recent years after sex- and race-adjustments and age-standardizations. <https://pubmed.ncbi.nlm.nih.gov/33553981/>

KRAS mutation is independently associated with tumor deposit presence and a worse overall survival in CRC patients. <https://pubmed.ncbi.nlm.nih.gov/32394229/>

the male gender is associated with both synchronous adenoma and cancer, and synchronous adenoma, sessile serrated lesion and cancer, while index polyp site is associated with synchronous adenoma and cancer. <https://pubmed.ncbi.nlm.nih.gov/31851088/>

Comparison of performance of different machine learning algorithms, including <https://pubmed.ncbi.nlm.nih.gov/33574440/>, <https://pubmed.ncbi.nlm.nih.gov/33415023/>, <https://pubmed.ncbi.nlm.nih.gov/32509383/>, <https://pubmed.ncbi.nlm.nih.gov/33307409/>

**Scan the QR code
on the right**
To join the ACACR annual meeting seminars at 3:00 PM ET (2:00 PM CT, 12 noon PT) on Fridays.



ADVERTISEMENT

May 28, 2021

Stop hate crimes and racism

We are physician and scientist organizations in North America. We vehemently condemn all forms of hatred, violence and racism in our society. While, sadly, these are not new issues, the recent uptick in discrimination and hate crimes against the Asian American and Pacific Islander community is devastating and unsettling to us all as a society.

The increasing hate crimes and violence towards Asian Americans and Pacific Islanders have incited fear and terror within our community. All human beings are free and equal in dignity and rights. No one should have to fear for their safety or be the victims of any kind of physical or emotional attacks due to their physical appearance or cultural and ethnic background. The right to freedom from discrimination is a fundamental human right—one that we must uphold.

Built upon and thriving on immigration, the United States has always been a beacon of hope and justice to attract talented and hardworking immigrants from all over the world. Immigrants and their descendants have been and will continue to make tremendous and incontrovertible contributions to the growth and prosperity of the US. Just for the scientific endeavor alone, over 30% of the Nobel Prize Laureates in the United States during 1901-2013 were born in other countries, including 6 from Greater China, 5 from Japan, and 7 from India^{1,2}. Asian Americans and Pacific Islanders are a vital and integral part of this diverse nation.

We call on you to denounce in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders. We call on you to pursue racial equality and tolerance in the United States and beyond. We call on you to stand strong and together with us.

- American Association of Chinese Rehabilitation Physiatrists (AACRP)
- Asian American Accountable Care Organization (AAACO)
- Asian American Health Center (AAHC)
- Association of Chinese American Physicians (ACAP)
- Association of Chinese Americans in Cancer Research (ACACR)
- Association of Chinese Geneticists in America (ACGA)
- BayHelix Group
- Chinese American Allergy Professionals (CAAP)
- Chinese American BioMedical Association (CABA)
- Chinese American Biopharmaceutical Society (CABS)
- Chinese American Diabetes Association (CADA)
- Chinese American Doctor Association (Greater Baltimore region) (CADA)
- Chinese American Heart Association (CnAHA)
- Chinese American Hematologist and Oncologist Network (CAHON)
- Chinese American Independent Practice Association (CAIPA)
- Chinese American Lung Association (CALA)
- Chinese American Medical Association of California (CAMAC)
- Chinese American Neurological Association (CANA)
- Chinese American Pathologists Association (CAPA)
- Chinese American Society of Anesthesiology (CASA)
- Chinese Biological Investigators Society (CBIS)
- Chinese Biopharmaceutical Association, USA (CBA)
- Chinese Canadian Medical Society B.C. (CCMSBC)
- Chinese Community Accountable Care Organization (CCACO)
- Eastern Chinese American Physicians IPA, Inc. (ECAP)
- Excelsior Integrated Medical Group (EIMG)
- San Diego Chinese American Physicians Association (SDCAPA)
- Sino-American Biotechnology and Pharmaceutical Professional Association (SABPA)
- Sino-American Network for Therapeutic Radiology and Oncology (SANTRO)
- Society for Chinese Neuroscientists (SCN)
- Society of Chinese American Physician Entrepreneurs (SCAPE)
- Society of Chinese Bioscientists in America (SCBA)
- Society of Chinese Bioscientists in America Hematology Division (SCBA HD)
- Washington Association of Chinese American Physicians (WACAP)

References:

1. Institute for Immigration Research, Research brief, November 2013, http://s3.amazonaws.com/chssweb/documents/20864/original/Nobel_Prize_Research_Brief_Final.pdf?1447975594
2. <http://www.leadthecompetition.in/GK/nobel-prize-winners-from-india.html>

Source: Sciencemag.org

Funding Alerts (May-June 2021)

R01 grants

[Notice of Participation of the Office of Research on Women's Health \(ORWH\) in PAR-20-238, "Intervention Research to Improve Native American Health \(R01 Clinical Trial Optional\)"](#)
(NOT-OD-21-133)
Office of Research on Women's Health

U grants

- [Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program \(CAP-IT\) Centers \(U54 Clinical Trial Not Allowed\)](#)
(NOT-CA-21-079)
National Cancer Institute
- [Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program \(CAP-IT\) Data and Resource Coordination Center \(DRCC\) \(U24 Clinical Trial Not Allowed\)](#)
(NOT-CA-21-080)
National Cancer Institute
- [Notice of Addition of Information for RFA-RM-21-021 - Transformative Research to Address Health Disparities and Advance Health Equity \(U01 Clinical Trial Allowed\)](#)
(NOT-RM-21-027)
Office of Strategic Coordination (Common Fund)
- [Notice of Addition of Information for RFA-RM-21-022 - Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions \(U01 Clinical Trial Allowed\)](#)
(NOT-RM-21-028)
Office of Strategic Coordination (Common Fund)
- [Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Target Discovery and Development \(CTD2\) \(U01 Clinical Trial Not Allowed\)](#)
(NOT-CA-21-081)
National Cancer Institute
- Assay Validation of High-Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed); [PAR-20-313 & PAR-20-314](#)
National Cancer Institute
- [Integration, Dissemination, and Evaluation \(BRIDGE\) Center for the NIH Bridge to Artificial Intelligence \(Bridge2AI\) Program \(U54 Clinical Trial Not Allowed\)](#)
(RFA-RM-21-023)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): August 20, 2021
- [Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries \(U01 Clinical Trial Optional\)](#)(NOT-CA-21-084)National Cancer Institute

R21/R03 grants

- [Notice of Participation of the Office of Research on Women's Health \(ORWH\) in PAR-20-214, "Research to Improve Native American Health \(R21 Clinical Trials Optional\)"](#)
(NOT-OD-21-132)
Office of Research on Women's Health
-

About the President



Lin Zhang, PhD, Professor, UPMC, Pittsburgh, PA

Dr. Lin Zhang received his B.S. from Sichuan University in 1990, and Ph.D. in Molecular Biology from University of Southern California (USC) in 1995. After postdoctoral training with Dr. Bert Vogelstein at Johns Hopkins, he joined the faculty at University of Pittsburgh Cancer Institute in 2002. He was promoted to tenured Associate Professor in 2008 and full Professor in 2015. His research interests include designing and conducting molecular, cellular, and animal studies to determine the mechanisms of colorectal cancer therapy and prevention. His research has been continuously supported by National Cancer Institute (NCI) since 2004. Dr. Zhang has authored over 130 research and review articles with over 25,000 citations and H-index of 60. He served as a standing member of the NIH Drug Development and Pharmacology (DMP) study section, and a member of the AACR (American Association for Cancer

Research) Special Conferences Committee. He is on the editorial boards of Cancer Research and other journals. Dr. Zhang was a founding member of ACACR and previously in charge of nominating ACACR members to AACR.

Funding Alerts (May-June 2021), cont'd.

Others

- [NIH Directors New Innovator Award Program \(DP2 Clinical Trial Optional\) \(RFA-RM-21-016\)](#)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): August 20, 2021
- [Launching Future Leaders in Global Health \(LAUNCH\) Research Training Program \(D43 Clinical Trial Optional\) \(RFA-TW-21-004\)](#)
John E. Fogarty International Center
National Cancer Institute
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Office of Research on Women's Health
Application Receipt Date(s): August 20, 2021
- [Method to Extend Research in Time \(MERIT\) Award Extension Request \(Type 4 Clinical Trial Optional\) \(PAR-21-138\)](#)
National Cancer Institute
Application Receipt Date(s): The first Application Due Date is July 7, 2021. NCI ESI MERIT Award Extension requests are due during the penultimate award year, either on March 1, July 1, or November 1. For more details, refer to the deadlines table for the NCI ESI MERIT Awards. Recipients are encouraged to contact the NCI program director and grants management specialist assigned to the R37 award for details. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. This funding opportunity announcement is specifically for currently funded NCI ESI MERIT recipients to request the second phase of the initial award.
- [Notice of Pre-Application Webinars for the High-Risk, High-Reward Research Program's Pioneer \(RFA-RM-21-015\), New Innovator \(RFA-RM-21-016\), Transformative Research \(RFA-RM-21-017\), and Early Independence \(RFA-RM-21-018\) Awards \(NOT-RM-21-017\)](#)Office of Strategic Coordination (Common Fund)
- [Request for Information \(RFI\): Inviting Input on NIAAAs 2022-2026 Strategic Plan Outline \(NOT-AA-21-033\)](#)
National Institute on Alcohol Abuse and Alcoholism
- [Request for Information \(RFI\): Input for National Cancer Institute \(NCI\) Pediatric Immunotherapy Network \(NOT-CA-21-086\)](#)National Cancer Institute

Genes & Diseases

An international journal for molecular and translational medicine

Journal Metrics

CiteScore: 7.5 (2020)

Impact Factor: 4.803 (2019/2020)

Source Normalized Impact per Paper (SNIP): 1.312 (2020)

SCImago Journal Rank (SJR): 1.614 (2020)

Published Quarterly


Open Access

ISSN: 2352-3042

Types of Articles

Full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch.

Review Speed



Call for Papers

Email: editor@genesndiseases.com

Home page: <https://www.journals.elsevier.com/genes-and-diseases/>

Journal page: <https://www.sciencedirect.com/journal/genes-and-diseases>

In partnership with ACACR





Postdoctoral Positions at Rutgers CINJ

Rutgers Cancer Institute of New Jersey Postdoctoral positions are available in the Division of Radiation Cancer Biology at the Department of Radiation Oncology under the mentorship of Dr. Zhiyuan Shen. The postdoctoral appointees may participate in the studies of DNA repair and its influence on tumor response to treatment, 60S ribosome biogenesis, the role of non-histone lysine methylation in cell fate determination after DNA damage, and the mechanisms involved in the recovery of acquired bone marrow failure.

Housed in the Rutgers Cancer Institute of New Jersey, the Shen lab (<https://cinj.org/ShenLab>) is located at a vibrant and interdisciplinary basic/translational/clinical research facility in New Brunswick, NJ. Postdocs have abundant opportunities to interact

with a vast research community offered by Rutgers campuses, and participate in various career trainings and activities. New Brunswick has a convenient access to major cultural centers such as New York city and Philadelphia. Positions are available July 1st 2021 until filled. For interested candidates, please send CV to: shenzh@cinj.rutgers.edu or file a formal application at: <https://jobs.rutgers.edu/postings/133507>

FOX CHASE CANCER CENTER Researcher position in lymphoma translational research at Fox Chase Cancer Center

TEMPLE HEALTH

Master and PhD-level research positions are available in the laboratory of Dr. Y. Lynn Wang, MD, PhD at the Fox Chase Cancer Center (<https://www.foxchase.org/-lynn-wang>). Our laboratory is seeking a self-motivated and organized individual to join our translational research on lymphoma and CLL. Wang lab is one of the pioneering groups who explored the idea of targeting B-cell receptor (BCR) signaling in lymphoid malignancies before BCR-directed therapies became well-known and successful. The lab has contributed work to show that targeting specific components of the pathway blocked BCR signaling and generated anti-lymphoma effects.

Wang lab also works on characterizing the molecular mechanisms underlying drug sensitivity and resistance. The lab contributed significantly to the understanding of the mechanisms leading to primary and secondary resistance to SYK and BTK inhibition. In May 2014, the lab reported the first discovery of BTK^{C481S} mutation that confers ibrutinib (a BTK inhibitor) resistance in the NEJM. This has been followed by a series of studies elucidating the molecular mechanisms of primary and secondary resistance to ibrutinib in CLL and mantle cell lymphoma. In addition, the lab has developed strategies for overcoming such resistance based on molecular rationales, such as using HSP90 inhibitors to overcome MYC activation in MCL.

Wang Lab has contributed >70 papers to peer-reviewed medical and scientific literature. These include reports published in journals such as NEJM, Leukemia, JAMA Oncology, British Journal of Haematology, Oncogene, Blood and Blood Advances. Their article entitled "Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration

of alternative kinase inhibitors" is ranked as one of most highly cited papers published in Leukemia since 2015. The lab actively collaborates with industrial partners and provides opportunities for researchers who consider a future pharmaceutical career.

Individuals with background and expertise in molecular biology, cell biology, immunology, cancer biology, genomic studies and computational skills will be preferred. Knowledge and experience working with lymphomas/CLL will be an advantage. The individual will be expected to participate in research projects, foster collaborations, present and communicate research findings at meetings and conferences. The individual must have a master degree or above in a biomedical field. The exact position will be commensurate with the individual's education and research background.

Fox Chase Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center, one of only 41 centers in the country to qualify for this level of designation. Fox Chase offers a rich and supportive training environment and has consistently ranked high for training in the United States. Moreover, Fox Chase is part of the rich scientific and biotech environment in the Philadelphia region. Fox Chase has an excellent career placement record in academia and industry, as well as other careers in science.

If you share our passion for drug and biomarker development in lymphoma, please send 1) your CV, 2) a cover letter describing your expertise and scientific interests, and 3) name and contact information of three references to Dr. Wang at yue-lynn.wang@fcc.edu.

Postdoctoral Position at Yale University School of Medicine

The Research Lab of Chen Liu in the Department of Pathology at Yale University has an opening for a postdoctoral position. The lab is focused on understanding the pathogenesis and immunobiology of human solid tumors using quantitative pathology, genetic/epigenetic analysis, *in vitro/in vivo* cell models, and molecular biology to interrogate relevant immunomodulatory pathways and identify determinants of sensitivity and resistance to treatments, as well as to develop novel therapeutic approaches for cancer. Our lab has access to cutting-edge technology and has unique opportunities to develop translational research projects in human liver, GI and head and neck cancers. More information can be found at https://medicine.yale.edu/lab/chen_liu/research/



Yale University
School of Medicine

We are looking for a highly motivated individual interested in studying cancer immunology and/or cancer epigenetics. Interested applicants should hold a Ph.D. or MD/Ph.D. degree and a strong background in the field of immunology and/or translational oncology. The candidate should be self-motivated with a proven track record of productivity. In addition to individual projects, the lab encourages a collaborative and positive working environment with other lab members and throughout the University and Cancer Center.

The competitive candidate should have knowledge and expertise in the following areas:

Immune-oncology and immunomodulatory therapies

Solid tumor oncology, cancer epigenetics, and translational pathology

Advanced cancer diagnostics and immune-based anti-cancer therapeutics

Computational analysis of images and large datasets (optional, but preferred)

Smoking and E-cigarette smoking related pathology (optional)

Candidates with the following qualifications will be given preference:

Interest and expertise in the field of immune-oncology/cancer epigenetics

Productivity, quality of previous projects and independence

Ability and interest to work in translational research within a multidisciplinary team

Qualified candidates who are interested in applying should e-mail an application package, including: statement of interest, CV, and contact information for three references. Please send your application package to Kien Pham (kien.pham@yale.edu) and in the subject line include your last name to the job posting.

Faculty Position in Epidemiology at Rutgers School of Public Health

RUTGERS

School of Public Health

The Rutgers School of Public Health invites applications for a tenure track faculty position at the rank of Assistant Professor and/or Instructor in Epidemiology. The successful applicant will be expected to develop and sustain an independent research program, contribute to the teaching mission, mentor MPH and doctoral students, and actively engage with the communities we serve, directed by the following mission: "To advance health and well-being and prevent disease throughout New Jersey, the United States, and the world, by preparing students as public health leaders, scholars, and practitioners; conducting public health research and scholarship; engaging collaboratively with communities and populations; and actively advocating for policies,

programs, and services through the lens of equity and social justice."

The ideal candidate will enhance our epidemiological core and complement or deepen our current department strengths, including but not limited to Chronic and Infectious Disease Epidemiology, Cancer Epidemiology, Nutrition Epidemiology, Social Epidemiology, and Modern Epidemiological Methods.

Posting Open Date: 06/09/2021

Post Close Date: 10/01/2021

Website: <https://jobs.rutgers.edu/postings/134406>

Department: SPH-Epidemiology

Salary: Commensurate With Experience

How to become a member of ACACR 如何成为ACACR 协会会员

感谢大家对ACACR 的关心和鼓励，更感谢许多志愿者们的付出。我们的财务李勇已把协会的银行帐户，PayPal 帐户开好；我们 IT 小组的戴木水已经将网上自动付款体系建成；我们会员小组的席亚光已将会员注册的表格等设计好。下面是如何成为我们协会会员了。

我们有两种会员制，普通会员 (regular member) 和 临时会员 (associate member)。普通会员又分终生会员 (lifetime membership) 以及年度会员，前者会费 \$500, 后者会费每两年\$100。临时会员暂不收费，但以后可能会有所改变。

目前我们还是半自动化注册（即有部分手工）。请到我们网站 acacr.org 在 “[membership](#)” 栏下载注册表，填好后电邮给表最后的邮件地址。

我们共有三种付会员费的方式：

1. 在我们网站上用Paypal(或信用卡)付 tacacr@outlook.com
2. 银行直接Transfer Money (Zelle, like Chase Quickpay) to tacacr@outlook.com.
3. 支票. 请写明付给 "Association of Chinese Americans in Cancer Research, Inc." 需要邮寄支票的，请与Dr. Yong Li 联系, Yong.Li@bcm.edu, 请在电邮上注明 ACACR member.

我们将在收到付款后五-七个工作日发出收据。

协会会员的益处：

协会普通会员和临时会员都可以参加WeChat 的讨论，信息交流，年会以及其他一些由ACACR 组织的活动。普通会员还有以下一些额外的福利。

- (1) 协会内部选举和被选举权；
- (2) 由ACACR 推荐去AACR 各种委员会和杂志编辑部；
- (3) 在我们协会网站上招人广告栏上发广告（微信群里的帖子会很快被淹没）；
- (4) 在我们协会网站上贴一些会议通知；
- (5) 在我们协会每月一次的 Newsletter 上登广告（非会员收费 \$20）；
- (6) 我们协会网站和 Newsletter “Research Highlights” 栏目中将优先选发协会会员刚发表的文章；
- (7) 今后ACACR 有小型奖励机会 (award opportunity), 将优先考虑我们的普通会员；
- (8) 今后购买ACACR 赞助商的物品时可能有折扣机会。

普通会员今后可能有的福利还包括会员学术交流活动 (annual retreat), 成员互助等。



SCAN ME to join the ACACR

ASSOCIATION OF
CHINESE
AMERICANS IN
CANCER RESEARCH

PO Box 1382,
Timonium, MD 21093

Phone: (443) 923-9498

Email: acacr@weebly.com

We are on the web
<http://www.acacr.org/>

Our Missions

Our mission is to prevent and cure cancer through fostering interactions and collaborations among Chinese Americans in all areas of cancer research including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment. ACACR also promotes interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities.



Volume 2, Issue 7

June 2021

Immediate past president's remarks

Dear colleagues,

It is really my honor to serve as the president of ACACR from 2019-2020. I am thankful for all your help to promote the mission of ACACR. These two years were not an easy time for all of us: we experienced a pandemic and live in an unfavorable geopolitical environment. Despite these, Chinese American cancer researchers keep making breakthroughs and significant contributions to cancer research, as exemplified by the studies highlighted in this newsletter. We have also expanded our membership, held both in person and online meetings and launched an ACACR affiliated journal Genes & Diseases. The dark clouds will pass and our mission that gives our work meaning is to prevent

and cure cancer. Let us press forward for this goal. Let us keep supporting the new leadership and actively participate in ACACR activities. I hope we can meet in person again next year in our annual meeting and have a great exchange of scientific ideas and a good laugh together.



Zhenkun Lou, PhD
President, 2019-2021
Professor of Pharmacology, Mayo Clinic

Management team ([web link](#))

Board of Directors

Shiyuan Cheng, PhD
Wei Gu, PhD
Yibin Kang, PhD
Jinsong Liu, MD, MA, PhD
Hua Lu, MD, PhD
Shaomeng Wang, PhD

President

Lin Zhang, PhD

President Elect

Gloria Su, PhD

General Secretary

Erxi Wu, PhD

Treasurer

Yong Li, PhD

Committee chair/co-

chair

Annual meeting
Gensheng Feng, PhD
Tongchuan He, MD, PhD
Binhua Zhou, MD, PhD

Audit

Zhaohui Feng, PhD

Fundraising

Bin Li, MD
Xing Fan, MD PhD

IT-support

Wenwei Hu, PhD
Mushui Dai, MD, PhD

Membership

Yaguang Xi, MD, PhD, MBA

Newsletters

Lanjing Zhang, MD
Shuhang Wang, MD

Past Presidents

2019-2021
Zhenkun Lou, PhD

2017-2018
Shiyuan Cheng, PhD



SCAN ME

To join the annual
meeting seminars

Call for submissions and volunteers

We would love to hear from you. Any suggestions or ideas are welcome. We also would like to invite you to join our newsletter team. If interested, please email lanjing.zhang@rutgers.edu